Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | Acasunlimab |
| Trade Name | |
| Synonyms | GEN1046|GEN-1046|GEN 1046|DuoBody-PD-L1x4-1BB|BNT 311|BNT-311|BNT311 |
| Drug Descriptions |
Acasunlimab (GEN1046) is a bispecific antibody that binds to and simultaneously targets PD-L1 and TNFRSF9 (4-1BB), potentially resulting in T-cell activation leading to increased anti-tumor immune response and decreased tumor growth (PMID: 35176764). |
| DrugClasses | Immune Checkpoint Inhibitor 150 PD-L1/PD-1 antibody 132 TNFRSF9 Antibody 36 |
| CAS Registry Number | NA |
| NCIT ID | C172194 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| Acasunlimab | Acasunlimab | 0 | 3 |
| Acasunlimab + Pembrolizumab | Acasunlimab Pembrolizumab | 0 | 4 |